Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: insights from ROCKET AF

BACKGROUND: ROCKET AF demonstrated the efficacy and safety of rivaroxaban compared with warfarin for the prevention of stroke and systemic embolism (SE) in patients with atrial fibrillation (AF). We examined baseline characteristics and outcomes in patients enrolled in Latin America compared with th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Blumer, Vanessa (VerfasserIn) , Rivera, Manuel (VerfasserIn) , Corbalán, Ramón (VerfasserIn) , Becker, Richard C. (VerfasserIn) , Berkowitz, Scott D. (VerfasserIn) , Breithardt, Günter (VerfasserIn) , Hacke, Werner (VerfasserIn) , Halperin, Jonathan L. (VerfasserIn) , Hankey, Graeme J. (VerfasserIn) , Mahaffey, Kenneth W. (VerfasserIn) , Nessel, Christopher C. (VerfasserIn) , Piccini, Jonathan P. (VerfasserIn) , Hellkamp, Anne S. (VerfasserIn) , Singer, Daniel E. (VerfasserIn) , Fox, Keith A. A. (VerfasserIn) , Patel, Manesh R. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2021
In: American heart journal
Year: 2021, Jahrgang: 236, Pages: 4-12
ISSN:1097-6744
DOI:10.1016/j.ahj.2021.02.004
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ahj.2021.02.004
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/abs/pii/S0002870321000363
Volltext
Verfasserangaben:Vanessa Blumer, Manuel Rivera, Ramón Corbalán, Richard C. Becker, Scott D. Berkowitz, Günter Breithardt, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Kenneth W. Mahaffey, Christopher C. Nessel, Jonathan P. Piccini, Anne S. Hellkamp, Daniel E. Singer, Keith A.A. Fox, and Manesh R. Patel

MARC

LEADER 00000caa a2200000 c 4500
001 1753562988
003 DE-627
005 20220819161108.0
007 cr uuu---uuuuu
008 210409s2021 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.ahj.2021.02.004  |2 doi 
035 |a (DE-627)1753562988 
035 |a (DE-599)KXP1753562988 
035 |a (OCoLC)1341403950 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Blumer, Vanessa  |e VerfasserIn  |0 (DE-588)1231099291  |0 (DE-627)175356459X  |4 aut 
245 1 0 |a Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America  |b insights from ROCKET AF  |c Vanessa Blumer, Manuel Rivera, Ramón Corbalán, Richard C. Becker, Scott D. Berkowitz, Günter Breithardt, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Kenneth W. Mahaffey, Christopher C. Nessel, Jonathan P. Piccini, Anne S. Hellkamp, Daniel E. Singer, Keith A.A. Fox, and Manesh R. Patel 
264 1 |c 2021 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 09.04.2021 
520 |a BACKGROUND: ROCKET AF demonstrated the efficacy and safety of rivaroxaban compared with warfarin for the prevention of stroke and systemic embolism (SE) in patients with atrial fibrillation (AF). We examined baseline characteristics and outcomes in patients enrolled in Latin America compared with the rest of the world (ROW). METHODS: ROCKET AF enrolled 14,264 patients from 45 countries. Of these, 1,878 (13.2%) were from 7 Latin American countries. The clinical characteristics and outcomes (adjusted by baseline characteristics) of these patients were compared with 12,293 patients from the ROW. Treatment outcomes of rivaroxaban compared with warfarin were also stratified by region. RESULTS: The annual rate of stroke/SE was similar in those from Latin American and ROW (P= .63), but all-cause and vascular death were significantly higher than in ROW (HR 1.40, 95% CI 1.20-1.64; HR 1.38, 95% CI 1.14-1.68; P< .001). Rates of major or nonmajor clinically relevant bleeding tended to be lower in Latin America (HR 0.89, 95% CI 0.80-1.0; P= .05). Rates of stroke and/or SE were similar with rivaroxaban and warfarin in patients from Latin America and ROW (HR 0.83, 95% CI 0.54-1.29 vs HR 0.89, 95% CI 0.75-1.07; interaction P= .77). CONCLUSIONS: Patients with AF in Latin America had similar rates of stroke and/or SE, higher rates of vascular death, and lower rates of bleeding compared with patients in the ROW. The effect of rivaroxaban compared with warfarin in Latin America was similar to the ROW. Further studies analyzing patient- and country-specific determinants of these regional differences in Latin America are warranted. 
700 1 |a Rivera, Manuel  |e VerfasserIn  |4 aut 
700 1 |a Corbalán, Ramón  |e VerfasserIn  |4 aut 
700 1 |a Becker, Richard C.  |e VerfasserIn  |4 aut 
700 1 |a Berkowitz, Scott D.  |e VerfasserIn  |4 aut 
700 1 |a Breithardt, Günter  |e VerfasserIn  |4 aut 
700 1 |a Hacke, Werner  |d 1948-  |e VerfasserIn  |0 (DE-588)12021699X  |0 (DE-627)080530346  |0 (DE-576)164358854  |4 aut 
700 1 |a Halperin, Jonathan L.  |e VerfasserIn  |4 aut 
700 1 |a Hankey, Graeme J.  |e VerfasserIn  |4 aut 
700 1 |a Mahaffey, Kenneth W.  |e VerfasserIn  |4 aut 
700 1 |a Nessel, Christopher C.  |e VerfasserIn  |4 aut 
700 1 |a Piccini, Jonathan P.  |e VerfasserIn  |4 aut 
700 1 |a Hellkamp, Anne S.  |e VerfasserIn  |4 aut 
700 1 |a Singer, Daniel E.  |e VerfasserIn  |4 aut 
700 1 |a Fox, Keith A. A.  |e VerfasserIn  |4 aut 
700 1 |a Patel, Manesh R.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t American heart journal  |d Amsterdam [u.a.] : Elsevier, 1925  |g 236(2021), Seite 4-12  |h Online-Ressource  |w (DE-627)313061718  |w (DE-600)2003210-9  |w (DE-576)090883500  |x 1097-6744  |7 nnas  |a Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America insights from ROCKET AF 
773 1 8 |g volume:236  |g year:2021  |g pages:4-12  |g extent:9  |a Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America insights from ROCKET AF 
856 4 0 |u https://doi.org/10.1016/j.ahj.2021.02.004  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/abs/pii/S0002870321000363  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210409 
993 |a Article 
994 |a 2021 
998 |g 12021699X  |a Hacke, Werner  |m 12021699X:Hacke, Werner  |d 50000  |e 50000PH12021699X  |k 0/50000/  |p 7 
999 |a KXP-PPN1753562988  |e 390427628X 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1753562988","id":{"doi":["10.1016/j.ahj.2021.02.004"],"eki":["1753562988"]},"language":["eng"],"physDesc":[{"extent":"9 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 09.04.2021"],"person":[{"given":"Vanessa","role":"aut","display":"Blumer, Vanessa","family":"Blumer","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Manuel","display":"Rivera, Manuel","family":"Rivera","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Ramón","display":"Corbalán, Ramón","family":"Corbalán","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Richard C.","display":"Becker, Richard C.","family":"Becker","roleDisplay":"VerfasserIn"},{"given":"Scott D.","role":"aut","display":"Berkowitz, Scott D.","family":"Berkowitz","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Breithardt, Günter","family":"Breithardt","given":"Günter","role":"aut"},{"family":"Hacke","display":"Hacke, Werner","roleDisplay":"VerfasserIn","role":"aut","given":"Werner"},{"roleDisplay":"VerfasserIn","family":"Halperin","display":"Halperin, Jonathan L.","given":"Jonathan L.","role":"aut"},{"given":"Graeme J.","role":"aut","roleDisplay":"VerfasserIn","display":"Hankey, Graeme J.","family":"Hankey"},{"role":"aut","given":"Kenneth W.","family":"Mahaffey","display":"Mahaffey, Kenneth W.","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Nessel, Christopher C.","family":"Nessel","role":"aut","given":"Christopher C."},{"role":"aut","given":"Jonathan P.","roleDisplay":"VerfasserIn","family":"Piccini","display":"Piccini, Jonathan P."},{"given":"Anne S.","role":"aut","family":"Hellkamp","display":"Hellkamp, Anne S.","roleDisplay":"VerfasserIn"},{"display":"Singer, Daniel E.","family":"Singer","roleDisplay":"VerfasserIn","given":"Daniel E.","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Fox","display":"Fox, Keith A. A.","given":"Keith A. A.","role":"aut"},{"role":"aut","given":"Manesh R.","display":"Patel, Manesh R.","family":"Patel","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America","subtitle":"insights from ROCKET AF","title":"Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America"}],"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"2021"}],"name":{"displayForm":["Vanessa Blumer, Manuel Rivera, Ramón Corbalán, Richard C. Becker, Scott D. Berkowitz, Günter Breithardt, Werner Hacke, Jonathan L. Halperin, Graeme J. Hankey, Kenneth W. Mahaffey, Christopher C. Nessel, Jonathan P. Piccini, Anne S. Hellkamp, Daniel E. Singer, Keith A.A. Fox, and Manesh R. Patel"]},"relHost":[{"id":{"eki":["313061718"],"zdb":["2003210-9"],"issn":["1097-6744"]},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"recId":"313061718","titleAlt":[{"title":"AHJ"}],"note":["Gesehen am 21.09.2020"],"title":[{"subtitle":"AHJ","title":"American heart journal","title_sort":"American heart journal"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"1925","publisherPlace":"Amsterdam [u.a.] ; St. Louis, Mo.","publisher":"Elsevier ; Mosby","dateIssuedDisp":"1925-"}],"pubHistory":["1.1925 -"],"disp":"Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America insights from ROCKET AFAmerican heart journal","part":{"volume":"236","year":"2021","pages":"4-12","text":"236(2021), Seite 4-12","extent":"9"}}]} 
SRT |a BLUMERVANERIVAROXABA2021